Cellestis
Qiagen Completes Cellestis Acquisition
NEW YORK (GenomeWeb News) – Qiagen today said that it has completed the acquisition of all of the ordinary shares of Melbourne, Australia-based Cellestis for A$3.80 (US$4.04) per share.
Australian Court Approves Qiagen's Purchase of Cellestis Shares
NEW YORK (GenomeWeb News) – Cellestis announced on Tuesday that the Supreme Court of Victoria in Australia has approved Qiagen's acquisition of its ordinary shares by way of a Scheme of Arrangement.
Cellestis Shareholders OK Acquisition by Qiagen
Shareholders overwhelmingly approved an amended proposal that will result in Qiagen paying around $374 million to acquire the Australian firm.
Qiagen Increases Offer Price for Cellestis Acquisition
Qiagen's offer represents a premium of roughly 41 percent premium to the three-month volume-weighted average price of Cellestis' shares ending on April 1.